BackgroundRapid identification of causative agents from positive blood culture (PBC) can aid earlier targeted therapy, as well as reduce mortality, length of stay, and costs associated with systemic infections. The BioFire® Blood Culture Identification 2 (BCID2) Panel being developed by BioFire Diagnostics, LLC, aims to maintain or improve the performance of the BioFire® FilmArray® Blood Culture Identification (BCID) Panel with updated and novel assays (15 new analytes: six antimicrobial resistance (AMR), six bacterial, and three fungal analytes). The performance of an RUO BioFire BCID2 Panel during a prospective pilot study is compared with standard of care (SoC), as well as independent PCR comparator assay (compPCR) results.MethodsTwo pilot sites enrolled de-identified PBC (<24 hours post-positivity) for which clinician-ordered SoC tests had been performed. Aliquots of residual PBC and isolates were frozen for compPCR testing of AMR markers and discrepancy resolution. 100 aerobic PBC (A-PBC) and 85 anaerobic PBC (AN-PBC) were tested with the BioFire BCID2 Panel; 70 A-PBCs and 56 AN-PBCs were concurrently tested on BioFire BCID Panel. Also, isolates from PBCs positive for AMR markers were tested using compPCR.ResultsThe BioFire BCID2 Panel results matched SoC results in 176/177 detections from 100 A-PBC, and in 167/168 detections from 85 AN-PBC. Both BioFire panels detected Candida glabrata and Candida parapsilosis from an A-PBC with only C. parapsilosis SOC result; interestingly, C. glabrata was detected by SoC in the paired AN-PBC. False-positive Bacteroides fragilis detection in an AN-PBC was resolved favorably by compPCR. Two patient samples, positive in both A-PBC and AN-PBC by SoC, were not detected by either the Staphylococcus epidermidis or the Staphylococcus spp. assays on the BioFire BCID2 Panel. All 26 AMR marker detections in both types of PBC were concordant with either SoC or compPCR results.ConclusionWith an expanded menu, >99% specificity, and >97% sensitivity, the BioFire BCID2 Panel is expected to provide rapid and accurate results for key pathogens associated with systemic infections, as well as important AMR markers.RUO products used in this study have not been evaluated by the FDA or other regulatory agencies for In Vitro Diagnostic use.Disclosures U. Spaulding, BioFire Diagnostics, LLC: Employee, Salary. J. Stone, BioFire Diagnostics, LLC: Employee, Salary. K. Koch, BioFire Diagnostics, LLC: Employee, Salary. J. Antosch, BioFire Diagnostics, LLC: Employee, Salary. M. Jones, BioFire Diagnostics, LLC: Employee, Salary. Z. Lu, BioFire Diagnostics, LLC: Employee, Salary. T. Todorov, BioFire Diagnostics, LLC: Employee, Salary. S. Kerr, BioFire Diagnostics, LLC: Employee, Salary. K. Holmberg, BioFire Diagnostics, LLC: Employee, Salary. M. Rogatcheva, BioFire: Employee, Salary.
BackgroundRapid diagnosis of causative agents of bloodstream infections improves patient outcomes and antibiotic stewardship. BioFire Diagnostics, LLC, is developing the BioFire® Blood Culture Identification 2 (BCID2) Panel, increasing the coverage of the BioFire® FilmArray® Blood Culture Identification (BCID) Panel for key pathogens and antimicrobial resistance (AMR) markers in aerobic and anaerobic positive blood culture (PBC). This revision expands the menu from 27 to 42 targets, with 26 bacterial (14 revised, six new) and seven fungal analytes (two revised, three new), as well as nine AMR markers (one revised, six new). Notable additions include the anaerobe Bacteroides fragilis, the emerging fungus Candida auris, and the mobile colistin resistance gene, mcr-1. This study details the reactivity and specificity of an RUO BioFire BCID2 panel.MethodsThe prototype was tested with fungal and bacterial isolates, some carrying AMR markers, at two sites by multiple operators. Reactivity was assessed at 106 CFU/mL for 301 analytes, and specificity at 108 CFU/mL for 43 on-panel and 93 off-panel strains. Evaluation included multiple strains for species level and AMR marker assays, as well as multiple species for family/genus level assays. Concordance with standard of care (SoC) results was examined for 126 archived PBC.ResultsTesting against 136 on-panel organisms, phylogenetic-neighbors, and normal cutaneous flora, showed 100% specificity for 41/42 targets. Reactivity was confirmed for 346/351 target analytes, and comprehensive detection was observed for the revised family-level Enteric assay (90/90) and genus-level Staphylococcus spp. (51/51), Streptococcus spp. (17/17), and Candida spp. (67/71) assays. The prototype showed excellent sensitivity (97.1%) and specificity (99.7%) compared with SoC with archived PBC.ConclusionPerformance of this RUO BioFire BCID2 Panel indicates that many key pathogens implicated in bloodstream infections can be identified with high sensitivity and specificity, and highlights the utility of the expanded menu to provide actionable information. Future panel versions will address observed deficiencies.RUO products used in this study have not been evaluated by the FDA or other regulatory agencies for In Vitro Diagnostic use.Disclosures J. Antosch, BioFire Diagnostics, LLC: Employee, Salary. U. Spaulding, BioFire Diagnostics, LLC: Employee, Salary. J. Stone, BioFire Diagnostics, LLC: Employee, Salary. C. Later, BioFire Diagnostics, LLC: Employee, Salary. K. Koch, BioFire Diagnostics, LLC: Employee, Salary. I. Kavetska, BioFire Diagnostics, LLC: Employee, Salary. H. Ton, BioFire Diagnostics, LLC: Employee, Salary. C. Alberti-Segui, bioMérieux: Employee, Salary. A. Grange, bioMereiux, Inc.: Employee, Salary. C. Dubost, bioMérieux: Employee, Salary. M. Rogatcheva, BioFire: Employee, Salary.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.